Canigou Capital is partnering with with VaremTech GMBH an established biogas developer for the development of 6 biogas plants in Germany. These biogas plants are situated in Northern Germany, with he first project being near Hamburg and is already operational. The scale of these development projects are still in discussions and more information about this investment opportunity will be updated soon.
Why Bio gas in Germany?
Germany is the leading country in Europe for biogas production. There are currently more than 9000 biogas plants in Germany and the German government have set stable feed in tariffs for the biogas industry. The German government plant to become carbon neutral by 2050, which is in line with EU initiatives. In order to achieve this the use of fossil fuels needs to be reduced every year by 2030. The government supports all green energy projects, notably biogas as it helps the agricultural sector to reduce waste production. The waste used in anaerobic digestion, which produces biogas is most often waste from farms, such as manure or crops. The agricultural industry is one of the main producers of greenhouse gases and biogas plants allow farmers to reduce this waste and at the same time produce gas which can be sold straight back into the national gas grid. This has become a lucrative side business for many farmers in Germany over the past 15 years. However, the government are now encouraging biogas plants to expand or introduce multiple renewable energy sources, such as integrating solar or wind to biogas plants or vice versa.
Bio Germany Ltd is to be an investment vehicle set up to capitalise on the clear opportunities present in the French solar market. Specifically, Bio Germany Ltd has partnered with a local developer and we will develop a minimum of four projects. We will commit funding to the projects only when a lease option has been agreed with a land owner, and we will work to progress them all the way to Ready To Build (RTB) status.
Bio Germany will initially develop two projects with the developer and take these to RTB stage. Once these first two projects are sold at the end of year one, the sale proceeds will be reinvested into two additional projects which will also be developed to RTB stage and sold.
The estimated time to complete a minimum of 4 projects is 24 – 36 months.
Investment into the Bio Germany Ltd investment vehicle will be available soon. Please fill in the contact details at the bottom of this page and we will email you when this project is launched.
Bio Germany Ltd (to be formed) will be registered in England under Company Number with principal place of business at 71-75 Shelton Street, London, Greater London, United Kingdom, WC2H 9JQ
RISK WARNING: The information contained in this website is prepared for general circulation and is intended to provide information only. It is not intended to be constructed as a solicitation for the sale of any particular investment nor as investment advice and does not have regard to the specific investment objectives, financial situation, and particular needs of any person to whom it is presented. In particular, the information contained on this site is not intended for distribution to, or use by, any person or entity in the United Stated of America (being residents of the United States of America or partnerships or corporations organised under the laws of the United States of America or any state of territory thereof) or any other jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Bio Germany Ltd. or any affiliates to any requirement to be registered or authorised within such jurisdiction or country. The information contained herein is not intended to be passed to third parties without our prior consent and may not be reproduced in whole or in part, without the permission of Bio Germany Ltd. The value of your investments and the income from them can fall as well as rise. An investor may not get back the amount of money invested. Past performance and forecasts are not reliable indicators of future results. Currency denominated investments are subject to fluctuations in exchange rates that could have a positive or adverse effect on the value of, and income from, the investment. Investors should consult their professional advisers on the possible tax and other consequences of holding such investments. The information in this email and any files transmitted with it are confidential and may be legally privileged. This email and any files transmitted with it are intended solely for the addressee or entity to whom they are addressed. Access to this email by anyone else is unauthorised. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. Any opinions expressed in the email are those of the individual and not necessarily those of Bio Germany Ltd. This website may contain specific market comment and indicative prices; this is for information purposes only and in no way constitutes advice to buy or sell. Bio Germany Ltd. accepts no responsibility for any actions taken by the recipient. No representation is made that this website or any attachments are free of viruses. Virus scanning is recommended and is the responsibility of the recipient.